For example, modification of NK cells with a chimeric receptor consisting of the NK cell activating receptor NKG2D, DNAX-activation protein 10 (DAP10) and CD3ζ led to increased cytotoxic activity against cancer cell lines and improved activity in an osteosarcoma mouse model (29, 30). This evidence concerns the gene KLRK1 and cancer.